EGFR

Summary

Gene Symbol: EGFR
Description: epidermal growth factor receptor
Alias: ERBB, ERBB1, HER1, PIG61, mENA, avian erythroblastic leukemia viral (v-erb-b) oncogene homolog, cell growth inhibiting protein 40, cell proliferation-inducing protein 61, proto-oncogene c-ErbB-1, receptor tyrosine-protein kinase erbB-1
Species: human

Top Publications

  1. ncbi Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
    Thomas J Lynch
    Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston 02129, USA
    N Engl J Med 350:2129-39. 2004
  2. ncbi EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
    J Guillermo Paez
    Departments of Medical Oncology and Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Science 304:1497-500. 2004
  3. pmc EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib
    William Pao
    Program in Cancer Biology and Genetics and Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 101:13306-11. 2004
  4. ncbi EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
    Susumu Kobayashi
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA
    N Engl J Med 352:786-92. 2005
  5. doi Screening for epidermal growth factor receptor mutations in lung cancer
    Rafael Rosell
    Catalan Institute of Oncology and Autonomous University of Barcelona, Hospital Germans Trias i Pujol, Barcelona, Spain
    N Engl J Med 361:958-67. 2009
  6. ncbi An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor
    Xuewu Zhang
    Department of Molecular and Cell Biology, Howard Hughes Medical Institute, University of California, Berkeley, 94720, USA
    Cell 125:1137-49. 2006
  7. pmc BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
    D Li
    Department of Medical Oncology, Dana Farber Cancer Institute, MA, USA
    Oncogene 27:4702-11. 2008
  8. ncbi c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function
    J S Biscardi
    Department of Microbiology and Cancer Center, Box 441, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA
    J Biol Chem 274:8335-43. 1999
  9. ncbi Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1
    G Levkowitz
    Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel
    Mol Cell 4:1029-40. 1999
  10. pmc Multiple mechanisms collectively regulate clathrin-mediated endocytosis of the epidermal growth factor receptor
    Lai Kuan Goh
    Department of Pharmacology, School of Medicine, University of Colorado Denver, Aurora, CO 80045, USA
    J Cell Biol 189:871-83. 2010

Detail Information

Publications319 found, 100 shown here

  1. ncbi Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
    Thomas J Lynch
    Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston 02129, USA
    N Engl J Med 350:2129-39. 2004
    ..have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR). However, about 10 percent of patients have a rapid and often dramatic clinical response...
  2. ncbi EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
    J Guillermo Paez
    Departments of Medical Oncology and Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Science 304:1497-500. 2004
    ..Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15of 58 unselected tumors from Japan and 1 of 61 from the United States...
  3. pmc EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib
    William Pao
    Program in Cancer Biology and Genetics and Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 101:13306-11. 2004
    Somatic mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene are reportedly associated with sensitivity of lung cancers to gefitinib (Iressa), kinase inhibitor...
  4. ncbi EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
    Susumu Kobayashi
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA
    N Engl J Med 352:786-92. 2005
    Mutations of the epidermal growth factor receptor (EGFR) gene have been identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors...
  5. doi Screening for epidermal growth factor receptor mutations in lung cancer
    Rafael Rosell
    Catalan Institute of Oncology and Autonomous University of Barcelona, Hospital Germans Trias i Pujol, Barcelona, Spain
    N Engl J Med 361:958-67. 2009
    Activating mutations in the epidermal growth factor receptor gene (EGFR) confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with advanced non-small-cell lung cancer...
  6. ncbi An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor
    Xuewu Zhang
    Department of Molecular and Cell Biology, Howard Hughes Medical Institute, University of California, Berkeley, 94720, USA
    Cell 125:1137-49. 2006
    The mechanism by which the epidermal growth factor receptor (EGFR) is activated upon dimerization has eluded definition...
  7. pmc BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
    D Li
    Department of Medical Oncology, Dana Farber Cancer Institute, MA, USA
    Oncogene 27:4702-11. 2008
    Genetic alterations in the kinase domain of the epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) patients are associated with sensitivity to treatment with small molecule tyrosine kinase inhibitors...
  8. ncbi c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function
    J S Biscardi
    Department of Microbiology and Cancer Center, Box 441, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA
    J Biol Chem 274:8335-43. 1999
    Accumulating evidence indicates that interactions between the epidermal growth factor receptor (EGFR) and the nonreceptor tyrosine kinase c-Src may contribute to an aggressive phenotype in multiple human tumors...
  9. ncbi Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1
    G Levkowitz
    Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel
    Mol Cell 4:1029-40. 1999
    ..that Cbl adaptor proteins directly control downregulation of the receptor for the epidermal growth factor (EGFR) by recruiting ubiquitin-activating and -conjugating enzymes...
  10. pmc Multiple mechanisms collectively regulate clathrin-mediated endocytosis of the epidermal growth factor receptor
    Lai Kuan Goh
    Department of Pharmacology, School of Medicine, University of Colorado Denver, Aurora, CO 80045, USA
    J Cell Biol 189:871-83. 2010
    Endocytosis of the epidermal growth factor receptor (EGFR) is important for the regulation of EGFR signaling...
  11. ncbi Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting
    John C Sok
    Department of Otolaryngology, and University of Pittsburgh Cancer Institute Biostatistics, University of Pittsburgh, Pennsylvania 15213, USA
    Clin Cancer Res 12:5064-73. 2006
    Epidermal growth factor receptor (EGFR) is overexpressed in head and neck squamous cell carcinoma (HNSCC) where expression levels correlate with decreased survival...
  12. doi Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer
    Hua Bai
    Peking University Cancer Hospital and Institute, Beijing, China
    J Clin Oncol 30:3077-83. 2012
    b>EGFR mutation is a predictor of epidermal growth factor receptor-tyrosine kinase inhibitor treatment response in patients with non-small-cell lung cancer (NSCLC)...
  13. ncbi PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib
    Jeffrey A Engelman
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
    Cancer Res 67:11924-32. 2007
    ..In this study, we evaluate the effectiveness of a novel compound, PF00299804, an irreversible pan-ERBB inhibitor...
  14. ncbi Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation
    Kaisa Haglund
    Ludwig Institute for Cancer Research, Husargatan 3, SE 75 124 Uppsala, Sweden
    Nat Cell Biol 5:461-6. 2003
    ..Thus, monoubiquitination is the principal signal responsible for the movement of RTKs from the plasma membrane to the lysosome...
  15. ncbi KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer
    Erminia Massarelli
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Clin Cancer Res 13:2890-6. 2007
    b>EGFR gene mutations and increased EGFR copy number have been associated with favorable response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKI) in patients with non-small-cell lung cancer (NSCLC)...
  16. pmc LIV-1 promotes prostate cancer epithelial-to-mesenchymal transition and metastasis through HB-EGF shedding and EGFR-mediated ERK signaling
    Hui Wen Lue
    Department of Biology, Georgia State University, Atlanta, Georgia, United States of America
    PLoS ONE 6:e27720. 2011
    ..growth factor (HB-EGF) from ARCaP(E) cells that elicited constitutive epidermal growth factor receptor (EGFR) phosphorylation and its downstream extracellular signal regulated kinase (ERK) signaling...
  17. pmc An unbiased screen identifies DEP-1 tumor suppressor as a phosphatase controlling EGFR endocytosis
    Gabi Tarcic
    Department of Biological Regulation, The Weizmann Institute of Science, Rehovot 76100, Israel
    Curr Biol 19:1788-98. 2009
    The epidermal growth factor (EGF) stimulates rapid tyrosine phosphorylation of the EGF receptor (EGFR)...
  18. ncbi Crystal structure of the ubiquitin binding domains of rabex-5 reveals two modes of interaction with ubiquitin
    Lorenza Penengo
    IFOM, the FIRC Institute for Molecular Oncology Foundation, Via Adamello 16, 20139 Milan, Italy
    Cell 124:1183-95. 2006
    ..The two binding surfaces allow Ub to interact simultaneously with different UBDs, thus opening new perspectives in Ub-mediated signaling...
  19. doi β1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells
    V Morello
    Molecular Biotechnology Center, University of Torino, Italy
    Oncogene 30:4087-96. 2011
    Lung cancer is the leading cause of cancer death worldwide. The epidermal growth factor receptor (EGFR) represents the main target for non-small cell lung cancer (NSCLC) therapy, as its overexpression or constitutive activation ..
  20. doi Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response
    Jenn Yu Wu
    Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    Clin Cancer Res 14:4877-82. 2008
    ..in patients of non-small cell lung cancer (NSCLC) with mutations in exon 20 of epidermal growth factor receptor (EGFR) are limited...
  21. doi Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer
    Pierre Laurent-Puig
    INSERM UMR S775 Molecular Basis of Xenobiotics Response, Paris, France
    J Clin Oncol 27:5924-30. 2009
    ..predictive of nonresponse and shorter survival in patients treated by anti-epidermal growth factor receptor (anti-EGFR) antibody for metastatic colorectal cancer (mCRC), leading the European Medicine Agency to limit its use to ..
  22. ncbi Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
    Shiqing Li
    Department of Physiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Cancer Cell 7:301-11. 2005
    Recent structural studies of epidermal growth factor receptor (EGFR) family extracellular regions have identified an unexpected mechanism for ligand-induced receptor dimerization that has important implications for activation and ..
  23. pmc An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors
    D Chitale
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Oncogene 28:2773-83. 2009
    ..This showed non-random patterns of copy number alterations significantly linked to EGFR and KRAS mutation status and to distinct clinical outcomes, and led to the discovery of a striking association of ..
  24. pmc Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment
    Natalia Jura
    Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA
    Cell 137:1293-307. 2009
    ..The formation of the activating juxtamembrane latch is prevented by the C-terminal tails in a structure of an inactive kinase domain dimer, suggesting how alternative dimers can prevent ligand-independent activation...
  25. ncbi The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling
    E J Lowenstein
    Department of Pharmacology, New York University Medical Center, New York 10016
    Cell 70:431-42. 1992
    ..elegans protein sem-5. It has been shown that sem-5 and two other genes called let-23 (EGFR like) and let-60 (ras like) lie along the same signal transduction pathway controlling C. elegans vulval induction...
  26. ncbi Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase
    Klaus Dittmann
    Division of Radiobiology and Molecular Environmental Research, Department of Radiation Oncology, University of Tubingen, 72076 Tubingen, Germany
    J Biol Chem 280:31182-9. 2005
    Ionizing radiation, but not stimulation with epidermal growth factor (EGF), triggers EGF receptor (EGFR) import into the nucleus in a probably karyopherin alpha-linked manner...
  27. pmc Pathobiological implications of the expression of EGFR, pAkt, NF-κB and MIC-1 in prostate cancer stem cells and their progenies
    Murielle Mimeault
    Department of Biochemistry and Molecular Biology, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, United States of America
    PLoS ONE 7:e31919. 2012
    ..the possibility of using a combination of specific oncogenic products, including epidermal growth factor receptor (EGFR), pAkt, nuclear factor-kappaB (NF-κB) and macrophage inhibitory cytokine-1 (MIC-1) as biomarkers and therapeutic ..
  28. ncbi Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer
    Michio Inukai
    Department of Cancer and Thoracic Surgery, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama, Japan
    Cancer Res 66:7854-8. 2006
    The threonine-to-methionine substitution at amino acid position 790 (T790M) of the epidermal growth factor receptor (EGFR) gene has been reported in progressing lesions after gefitinib treatment in non-small cell lung cancer (NSCLC) that ..
  29. doi EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset
    Kentaro Inamura
    Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Koto ku, Tokyo, Japan
    Mod Pathol 22:508-15. 2009
    ..clinicopathologically examined the characteristics of the EML4-ALK-positive cases, including the mutation status of EGFR, KRAS, and TP53, and whether they were of thyroid transcription factor-1 (TTF-1) cell lineage or not...
  30. pmc Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer
    Kirstine Roepstorff
    Department of Cellular and Molecular Medicine, The Panum Institute, University of Copenhagen, Blegdamsvej 3, 2200 Copenhagen N, Denmark
    Histochem Cell Biol 129:563-78. 2008
    ErbB receptors (EGFR (ErbB1), ErbB2, ErbB3, and ErbB4) are important regulators of normal growth and differentiation, and they are involved in the pathogenesis of cancer...
  31. pmc Use of immunohistochemical markers can refine prognosis in triple negative breast cancer
    Marc Tischkowitz
    Program in Cancer Genetics, McGill University, Montreal, Quebec, Canada
    BMC Cancer 7:134. 2007
    ..The IHC pattern that best defines basal-like tumors is under investigation and various combinations of ER, PR, HER2-, CK5/6+ and EGFR+ have been tested.
  32. doi Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer
    Sarah Park
    Department of Medicine, Division of Hematology Oncology, Hangang Sacred Heart Hospital, Hallym University School of Medicine, Seoul, Korea
    J Thorac Oncol 4:809-15. 2009
    For the identification of the patients who most likely benefit from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC), molecular assays are considered to be of paramount importance...
  33. doi Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy
    Chih Hsin Yang
    Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
    J Clin Oncol 26:2745-53. 2008
    ..To explore predictive factors for time to treatment failure (TTF) in chemotherapy-naive non-small-cell lung cancer (NSCLC) patients receiving gefitinib treatment...
  34. doi Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop
    Robert Pirker
    Medical University of Vienna, Vienna, Austria
    J Thorac Oncol 5:1706-13. 2010
    Activating somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor (EGFR) have recently been characterized in a subset of patients with advanced non-small cell lung cancer (NSCLC)...
  35. ncbi Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway
    Hui Wen Lo
    Cancer Cell 7:575-89. 2005
    Epidermal growth factor receptor (EGFR) exists in the nucleus of highly proliferative cells where it functions as a transcription factor...
  36. pmc Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)
    K Tamura
    Outpatients Treatment Center, National Cancer Center Hospital, 5 1 1, Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Br J Cancer 98:907-14. 2008
    ..was to evaluate the efficacy of gefitinib and the feasibility of screening for epidermal growth factor receptor (EGFR) mutations among select patients with advanced non-small cell lung cancer (NSCLC)...
  37. pmc Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma
    James Bean
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 14:7519-25. 2008
    Somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are associated with sensitivity of lung adenocarcinomas to the EGFR tyrosine kinase inhibitors, gefitinib and erlotinib...
  38. pmc Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK
    Alice T Shaw
    Department of Pathology, Massachusetts General Hospital, Warren 501c, 55 Fruit St, Boston, MA 02114, USA
    J Clin Oncol 27:4247-53. 2009
    ..To aid in identification and treatment of these patients, we examined the clinical characteristics and treatment outcomes of patients who had NSCLC with and without EML4-ALK...
  39. doi Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer
    B Corkery
    National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin
    Ann Oncol 20:862-7. 2009
    ..Epidermal growth factor receptor (EGFR) is frequently overexpressed in TNBC...
  40. ncbi Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
    Hisayuki Shigematsu
    Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX 75390 8593, USA
    J Natl Cancer Inst 97:339-46. 2005
    Mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene in lung cancers are associated with increased sensitivity of these cancers to drugs that inhibit EGFR kinase activity...
  41. ncbi High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan
    Shiu Feng Huang
    Division of Molecular and Genomic Medicine, National Health Research Institutes, Taipei, Taiwan
    Clin Cancer Res 10:8195-203. 2004
    Epidermal growth factor receptor (EGFR) mutations related to gefitinib responsiveness in non-small cell lung cancer have been found recently...
  42. pmc Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity
    Yuan Rong
    Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
    Cancer Res 69:2540-9. 2009
    ..Epidermal growth factor receptor (EGFR) amplification and PTEN loss are two common genetic alterations seen in GBM but not in lower-grade astrocytomas ..
  43. ncbi EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus
    Mitsuhiko Hanawa
    Department of Pathology, School of Medicine, University of Yamanashi, Japan
    Int J Cancer 118:1173-80. 2006
    Overexpression of epidermal growth factor receptor (EGFR) is observed in many cancers, sometimes accompanied by gene amplification...
  44. doi Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer
    Jian Yu
    Cell Signaling Technology, Inc, Danvers, Massachusetts, USA
    Clin Cancer Res 15:3023-8. 2009
    Activating mutations within the tyrosine kinase domain of epidermal growth factor receptor (EGFR) are found in approximately 10% to 20% of non-small-cell lung cancer (NSCLC) patients and are associated with response to EGFR inhibitors...
  45. doi Epithelial-mesenchymal-transition induced by EGFR activation interferes with cell migration and response to irradiation and cetuximab in head and neck cancer cells
    Carmen Holz
    Laboratory for Translational Radiobiology and Radiooncology, Department of Radiooncology, Charite Campus Mitte, Berlin, Germany
    Radiother Oncol 101:158-64. 2011
    The role of epithelial-mesenchymal transition (EMT) in the poor outcome of EGFR-overexpressing SCCHN was evaluated.
  46. pmc Induction of epidermal growth factor receptor expression by Epstein-Barr virus latent membrane protein 1 C-terminal-activating region 1 is mediated by NF-kappaB p50 homodimer/Bcl-3 complexes
    Natalie J Thornburg
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    J Virol 81:12954-61. 2007
    ..CTAR1 also uniquely upregulates the epidermal growth factor receptor (EGFR). In NPC, NF-kappaB p50/p50 homodimers and the transactivator Bcl-3 were detected on the EGFR promoter...
  47. doi A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells
    Miguel A Molina-Vila
    Catalan Institute of Oncology, Medical Oncology Service, Hosptial Germans Trias i Pujol, Badalona, Spain
    J Thorac Oncol 3:1224-35. 2008
    Detection of epidermal growth factor receptor (EGFR) mutations in advanced non-small cell lung cancer (NSCLC) patients has relied on DNA purification from biopsies, amplification, and sequencing...
  48. ncbi Assessment of epidermal growth factor receptor mutation by endobronchial ultrasound-guided transbronchial needle aspiration
    Takahiro Nakajima
    Department of Thoracic Surgery, Graduate School of Medicine, Chiba University, 1 8 1 Inohana, Chuo Ku, Chiba 260 8670, Japan
    Chest 132:597-602. 2007
    The presence of somatic mutations in epidermal growth factor receptor (EGFR) predicts the effectiveness of EGFR tyrosine kinase inhibitors (TKIs)...
  49. doi A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases
    Sara E Monaco
    Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA 15232, USA
    Hum Pathol 41:94-102. 2010
    Epidermal growth factor receptor (EGFR) and v-Ki-ras 2 (KRAS; viral Kirsten rat sacoma 2 oncogene homolog) oncogenes are predictors of response to EGFR-targeted therapy in lung carcinomas...
  50. doi Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer
    Hua Bai
    Department of Thoracic Medical Oncology Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing, China
    J Clin Oncol 27:2653-9. 2009
    Mutations in the epidermal growth factor receptor (EGFR) kinase domain can predict tumor response to tyrosine kinase inhibitors (TKIs) in non-small-cell lung cancer (NSCLC)...
  51. pmc Desmoglein 1-dependent suppression of EGFR signaling promotes epidermal differentiation and morphogenesis
    Spiro Getsios
    Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    J Cell Biol 185:1243-58. 2009
    ..In addition to serving as a rigid anchor between adjacent cells, this study implicates desmosomal cadherins as key components of a signaling axis governing epithelial morphogenesis...
  52. pmc Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients
    Kan V Lu
    Department of Pathology and Laboratory Medicine, University of California Los Angeles David Geffen School of Medicine, USA
    Cancer Res 69:6889-98. 2009
    Activating epidermal growth factor receptor (EGFR) mutations are common in many cancers including glioblastoma. However, clinical responses to EGFR inhibitors are infrequent and short-lived...
  53. pmc A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling
    Hadassa Waterman
    Department of Biological Regulation, The Weizmann Institute of Science, Rehovot 76100, Israel
    EMBO J 21:303-13. 2002
    Ligand-induced desensitization of the epidermal growth factor receptor (EGFR) is controlled by c-Cbl, a ubiquitin ligase that binds multiple signaling proteins, including the Grb2 adaptor...
  54. pmc A Fra-1-dependent, matrix metalloproteinase driven EGFR activation promotes human lung epithelial cell motility and invasion
    Pavan Adiseshaiah
    Department of Environmental Health Sciences, Bloomberg School of Public Health, Baltimore, Maryland, USA
    J Cell Physiol 216:405-12. 2008
    ..Furthermore, Fra-1 induced EGFR phosphorylation in an MMP-dependent manner, and an EGFR-specific inhibitor was able to block Fra-1-enhanced cell ..
  55. pmc HECT E3 ubiquitin ligase Nedd4-1 ubiquitinates ACK and regulates epidermal growth factor (EGF)-induced degradation of EGF receptor and ACK
    Qiong Lin
    Weis Center for Research, Geisinger Clinic, Danville, Pennsylvania 17822, USA
    Mol Cell Biol 30:1541-54. 2010
    ..an important role in ligand-induced and ubiquitination-mediated degradation of epidermal growth factor receptor (EGFR)...
  56. ncbi Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer
    Giuseppe Di Lorenzo
    Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi di Napoli Federico II, 80131 Naples, Italy
    Clin Cancer Res 8:3438-44. 2002
    ..Amplification and/or overexpression of c-erbB-2, a receptor closely related to the EGFR, has been recently involved in prostate cancer progression...
  57. doi Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center and Dana Farber Cancer Center, Harvard Medical School, Boston, MA 02114, USA
    J Clin Oncol 28:3076-83. 2010
    ..Resistance emerges after 9 to 12 months, primarily mediated by the T790M resistance mutation. We studied neratinib, an irreversible pan-ErbB TKI that may overcome T790M.
  58. ncbi Regulation of ubiquitin protein ligase activity in c-Cbl by phosphorylation-induced conformational change and constitutive activation by tyrosine to glutamate point mutations
    C Kenneth Kassenbrock
    Department of Pathology, University of Colorado Health Sciences Center, 4200 E Ninth Avenue, Denver, CO 80262, USA
    J Biol Chem 279:28017-27. 2004
    ..a Y371E mutant shows constitutive E3 activity while retaining the ability to bind epidermal growth factor receptor (EGFR)...
  59. pmc Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer
    Caterina Peraldo-Neia
    Department of Clinical Oncology, University of Torino Medical School, Institute for Cancer Research and Treatment, Candiolo, Turin, Italy
    BMC Cancer 11:31. 2011
    Activating mutations of the epidermal growth factor receptor (EGFR) confer sensitivity to the tyrosine kinase inhibitors (TKi), gefitinib and erlotinib...
  60. pmc Phosphorylation of Y845 on the epidermal growth factor receptor mediates binding to the mitochondrial protein cytochrome c oxidase subunit II
    Julie L Boerner
    Department of Microbiology and Cancer Center, University of Virginia Health System, Charlottesville, VA 22908, USA
    Mol Cell Biol 24:7059-71. 2004
    When co-overexpressed, the epidermal growth factor receptor (EGFR) and c-Src cooperate to cause synergistic increases in EGF-induced DNA synthesis, soft agar colony growth, and tumor formation in nude mice...
  61. doi Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer
    C H Gow
    Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    Ann Oncol 20:696-702. 2009
    Mutations of the epidermal growth factor receptor (EGFR) gene in non-small-cell lung cancer (NSCLC) patients predict the patients who will respond to EGFR tyrosine kinase inhibitor (TKI) treatment...
  62. ncbi Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis
    Fred R Hirsch
    Department of Pathology, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    J Clin Oncol 21:3798-807. 2003
    The epidermal growth factor receptor (EGFR) is frequently overexpressed in non-small-cell lung carcinoma (NSCLC), and EGFR inhibitors are promising new therapeutic agents...
  63. doi Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity
    Giuseppe Viale
    Division of Pathology, European Institute of Oncology, Milan, Italy
    Breast Cancer Res Treat 116:317-28. 2009
    ..significant worse disease-free and overall survival were observed in multivariate analysis, for patients with EGFR immunoreactivity in >or=50% invasive tumor cells (HR 2.39, 95% CI, 1.32-4.34, P = 0.004 for DFS; HR 2...
  64. pmc Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC
    A Kalikaki
    Laboratory of Tumor Cell Biology, School of Medicine, University of Crete, Heraklion, Crete, Greece
    Br J Cancer 99:923-9. 2008
    In non-small-cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) and K-RAS mutations of the primary tumour are associated with responsiveness and resistance to tyrosine kinase inhibitors (TKIs), respectively...
  65. doi EGFR R497K polymorphism is a favorable prognostic factor for advanced lung cancer
    Hidefumi Sasaki
    Department of Surgery II, Nagoya City University Medical School, 1 Kawasumi, Mizuho cho, Mizuho ku, Nagoya, 467 8601, Japan
    J Cancer Res Clin Oncol 135:313-8. 2009
    It has been reported that the R497K polymorphism of the epidermal growth factor receptor (EGFR) gene has attenuated functions in ligand binding, tyrosine kinase activation, and growth stimulation...
  66. doi Epidermal growth factor receptor mutation in gastric cancer
    Zhimin Liu
    Laboratory Center, The Second Affiliated Hospital of Dalian Medical University, 467 Zhongshan Road, Dalian, P R China
    Pathology 43:234-8. 2011
    Epidermal growth factor receptor (EGFR) and Kirsten-RAS (KRAS) mutations have been identified as predictors of response to EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer...
  67. ncbi Measuring IGF-1, ER-α and EGFR expression can predict tamoxifen-resistance in ER-positive breast cancer
    Kelvin Chong
    Department of Breast and Endocrine Surgery, St George s Hospital, London, UK
    Anticancer Res 31:23-32. 2011
    ..growth factor-1 (IGF-1) receptor (IGF-1l), oestrogen receptor-alpha (ERα), epidermal growth factor receptor (EGFR) and HER-2. We investigated which gene expressions could predict tamoxifen resistant breast cancer...
  68. ncbi Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab
    Yang Lu
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Res 67:8240-7. 2007
    Cetuximab is an epidermal growth factor receptor (EGFR)-blocking antibody that has been approved for treatment of patients with metastatic colorectal cancer...
  69. pmc Ubc4/5 and c-Cbl continue to ubiquitinate EGF receptor after internalization to facilitate polyubiquitination and degradation
    Kyohei Umebayashi
    Department of Cellular Regulation, Research Institute for Microbial Diseases, Osaka University, Osaka 565 0871, Japan
    Mol Biol Cell 19:3454-62. 2008
    c-Cbl is the E3 ubiquitin ligase that ubiquitinates the epidermal growth factor (EGF) receptor (EGFR)...
  70. doi EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan
    Toshimi Takano
    Division of Internal Medicine, Research Center for Cancer Prevention and Screening, National Cancer Center Hospital, Tokyo 104 0045, Japan
    J Clin Oncol 26:5589-95. 2008
    This study evaluated whether the presence of epidermal growth factor receptor (EGFR) mutations is a predictive marker for survival benefit from gefitinib and/or a prognostic marker in patients with advanced lung adenocarcinoma.
  71. pmc Activation of the EGFR/ERK pathway in high-grade mucoepidermoid carcinomas of the salivary glands
    B Lujan
    Department of Pathology, Hospital Clinic, IDIBAPS, University of Barcelona, Villarroel, 170, Barcelona 08036, Spain
    Br J Cancer 103:510-6. 2010
    ..High-grade tumours usually have an aggressive biological course and they require additional oncological treatment after surgery...
  72. doi Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry
    Akihiko Kawahara
    Department of Diagnostic Pathology, Kurume University Hospital, 67 Asahi Machi, Kurume 830 0011, Japan
    Lung Cancer 74:35-40. 2011
    Recently, we have reported that EGFR mutation-specific antibodies performed well in immunohistochemical analysis, with good sensitivity...
  73. pmc Hyaluronan facilitates transforming growth factor-β1-dependent proliferation via CD44 and epidermal growth factor receptor interaction
    Soma Meran
    Institute of Nephrology, University Hospital of Wales, Heath Park, Cardiff CF14 4XN, United Kingdom
    J Biol Chem 286:17618-30. 2011
    ..We also show that epidermal growth factor (EGF) and its receptor (EGFR) are essential for TGF-β1/HA/CD44-dependent proliferation...
  74. doi Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations
    Tommaso De Pas
    Medical Oncology Unit of Respiratory Tract and Sarcomas, European Institute of Oncology, Milan, Italy
    J Thorac Oncol 6:1895-901. 2011
    Mutations of the epidermal growth factor receptor (EGFR) have been proven to predict activity of the EGFR-tyrosine kinase inhibitors (EGFR-TKI), gefitinib and erlotinib...
  75. pmc Mutant p53 initiates a feedback loop that involves Egr-1/EGF receptor/ERK in prostate cancer cells
    L Sauer
    Vaccine Research Institute of San Diego, San Diego, CA 92121, USA
    Oncogene 29:2628-37. 2010
    ..epidermal growth factor), amphiregulin and epiregulin, resulting in autocrine activation of the EGF receptor (EGFR) and downstream MEK/ERK cascade...
  76. doi Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma
    S G Wu
    Dept of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    Eur Respir J 32:924-30. 2008
    ..Epidermal growth factor receptor (EGFR) gene mutations are usually detected in lung adenocarcinoma...
  77. ncbi Cbl-b-dependent coordinated degradation of the epidermal growth factor receptor signaling complex
    S A Ettenberg
    Genetics Department of the Medicine Branch and the Laboratory of Immune Cell Biology, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, Maryland 20889, USA
    J Biol Chem 276:27677-84. 2001
    ..finger and tyrosine kinase binding domains and requires binding of the Cbl-b protein to the activated EGF receptor (EGFR). Degradation of both the EGFR and the Cbl-b protein is blocked by lysosomal and proteasomal inhibitors...
  78. pmc Epidermal growth factor receptor translocation to the mitochondria: regulation and effect
    Michelle L Demory
    Department of Microbiology and The Cancer Center, University of Virginia, Charlottesville, Virginia 22908, USA
    J Biol Chem 284:36592-604. 2009
    Co-overexpression of the epidermal growth factor (EGF) receptor (EGFR) and c-Src frequently occurs in human tumors and is linked to enhanced tumor growth...
  79. doi EGFR fluorescence in situ hybridization-positive lung adenocarcinoma: incidence of coexisting KRAS and BRAF mutations
    Simion Chiosea
    Department of Pathology, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Hum Pathol 41:1053-60. 2010
    Despite growing evidence that epidermal growth factor receptor (EGFR) and v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation analysis is the most reliable predictor of the lung carcinoma response to EGFR-targeted ..
  80. ncbi Attenuation of EGF receptor signaling by a metastasis suppressor, the tetraspanin CD82/KAI-1
    E Odintsova
    CRC Institute for Cancer Studies, The University of Birmingham, Edgbaston, UK
    Curr Biol 10:1009-12. 2000
    ..We show here that the CD82/KAI-1 tetraspanin is directly associated with the EGF receptor (EGFR), and that ectopic expression of CD82/KAI-1 in epithelial cells specifically suppresses EGF-induced lamellipodial ..
  81. doi Somatostatin receptors 1 and 5 heterodimerize with epidermal growth factor receptor: agonist-dependent modulation of the downstream MAPK signalling pathway in breast cancer cells
    Heather L Watt
    Faculty of Medicine, Department of Experimental Medicine, McGill University, Royal Victoria Hospital, Montreal, QC, Canada
    Cell Signal 21:428-39. 2009
    ..tumour tissues express all five somatostatin receptors (SSTR1-5) and four epidermal growth factor receptors (ErbB1-4)...
  82. doi Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations
    I Garcia-Olivé
    Servei de Pneumologia, Hospital Germans Trias i Pujol, Carretera de Canyet s n, 08916 Badalona, Spain
    Eur Respir J 35:391-5. 2010
    The presence of somatic mutations of the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene in patients with advanced nonsmall cell lung cancer (NSCLC) correlates with a good response to tyrosine kinase inhibitors...
  83. doi EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases
    Katharina Schmid
    Clinical Institute of Pathology and Department of Medicine I, Medical University of Vienna, Waehringer Guertel 18 20, Vienna A 1090, Austria
    Clin Cancer Res 15:4554-60. 2009
    The epidermal growth factor receptor (EGFR) and its downstream factors KRAS and BRAF are mutated with different frequencies in non-small cell lung cancer and mutations predict clinical response to EGFR inhibitors...
  84. ncbi Ligand-induced dimer-tetramer transition during the activation of the cell surface epidermal growth factor receptor-A multidimensional microscopy analysis
    Andrew H A Clayton
    Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Royal Melbourne Hospital, Victoria 3050, Australia
    J Biol Chem 280:30392-9. 2005
    The epidermal growth factor receptor (EGFR) is a member of the erbB tyrosine kinase family of receptors...
  85. ncbi Generation of novel, secreted epidermal growth factor receptor (EGFR/ErbB1) isoforms via metalloprotease-dependent ectodomain shedding and exosome secretion
    Michael P Sanderson
    Tumor Immunology Program, German Cancer Research Center DKFZ, D010 TP3, Im Neuenheimer Feld 580, D 69120 Heidelberg, Germany
    J Cell Biochem 103:1783-97. 2008
    ..In this study, we sought to determine whether ErbB1 receptors are present within exosomes isolated from the human keratinocyte cell line, HaCaT, and whether exosome-..
  86. pmc PAI-1 mediates the TGF-beta1+EGF-induced "scatter" response in transformed human keratinocytes
    Jennifer Freytag
    Center for Cell Biology and Cancer Research, Albany Medical College, Albany, New York 12208, USA
    J Invest Dermatol 130:2179-90. 2010
    ..Moreover, EGFR signaling blockade or EGFR knockdown attenuated TGF-beta1-induced PAI-1 expression, implicating EGFR ..
  87. pmc Injury-induced innate immune response in human skin mediated by transactivation of the epidermal growth factor receptor
    Ole E Sørensen
    Section of Clinical and Experimental Infection Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden
    J Clin Invest 116:1878-85. 2006
    ..These data demonstrate that sterile wounding initiates an innate immune response that increases resistance to overt infection and microbial colonization...
  88. doi KRAS mutation status in primary nonsmall cell lung cancer and matched metastases
    Alexis B Cortot
    Department of Pulmonary Diseases, Lyon Sud Hospital Center, Claude Bernard University, Lyon, France
    Cancer 116:2682-7. 2010
    ..the mutation status of the v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) and epidermal growth factor receptor (EGFR) differed between primary tumors and matched distant metastases in nonsmall cell lung cancer (NSCLC).
  89. ncbi Bile acid regulates MUC2 transcription in colon cancer cells via positive EGFR/PKC/Ras/ERK/CREB, PI3K/Akt/IkappaB/NF-kappaB and p38/MSK1/CREB pathways and negative JNK/c-Jun/AP-1 pathway
    Hwa Young Lee
    Department of Gastroenterology, College of Medicine, Kangnam CHA Hospital, CHA University, Seoul, 650 9, Korea
    Int J Oncol 36:941-53. 2010
    ..constructs and EMSA showed that DCA upregulates MUC2 transcription via multiple pathways involving activation of EGFR/PKC/Ras/Raf-1/MEK1/ERK/CREB, PI3/Akt/IkappaB/NF-kappaB and p38/MSK1/CREB while DCA induced MUC2 transcription is ..
  90. doi Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma
    Jenifer L Marks
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Thorac Oncol 3:111-6. 2008
    Somatic mutations in EGFR (exons 19 and 21) and KRAS (exon 2) are found in lung adenocarcinomas and have potential prognostic value in patients with advanced disease...
  91. ncbi Epidermal growth factor receptor exposed to cigarette smoke is aberrantly activated and undergoes perinuclear trafficking
    Elaine M Khan
    Signal Transduction Laboratory, Department of Internal Medicine, University of California, School of Medicine, Davis, California, 95616, USA
    FASEB J 22:910-7. 2008
    ..in the gas phase of cigarette smoke (CS), induces aberrant phosphorylation of the epidermal growth factor receptor (EGFR), resulting in the lack of ubiquitination by c-Cbl, and impaired degradation...
  92. ncbi The epidermal growth factor receptor modulates the interaction of E-cadherin with the actin cytoskeleton
    R B Hazan
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Biol Chem 273:9078-84. 1998
    ....
  93. ncbi Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells
    April Thelemann
    OSI Pharmaceuticals, Inc, Farmingdale, NY 11735, USA
    Mol Cell Proteomics 4:356-76. 2005
    ..Anti-phosphotyrosine and anti-EGFr affinity chromatography, isotope-coded muLC-MS/MS, and immunoblot methods were combined to describe and measure ..
  94. pmc Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression
    Rafael Rosell
    Catalan Institute of Oncology, Badalona, Spain
    PLoS ONE 4:e5133. 2009
    ..A small fraction of non-squamous cell lung cancers harbor EGFR mutations, with improved outcome to gefitinib and erlotinib...
  95. doi Growth factor receptor expression in anal squamous lesions: modifications associated with oncogenic human papillomavirus and human immunodeficiency virus
    Francine Walker
    Department of Pathology, Institut de la Santé et de la Recherche Médicale Unité773, Hopital Bichat Claude Bernard, 75018 Paris, France
    Hum Pathol 40:1517-27. 2009
    ..Human immunodeficiency virus (HIV) promotes anal carcinogenesis. Epidermal growth factor receptor (EGFR), HER2/neu, c-Met, and vascular endothelial growth factor receptor-1 (VEGFR1) (tyrosine kinase growth factor ..
  96. doi Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer
    Tetsuya Mitsudomi
    Department of Thoracic Surgery, Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan
    FEBS J 277:301-8. 2010
    Epidermal growth factor receptor (EGFR) and its three related proteins (the ERBB family) are receptor tyrosine kinases that play essential roles in both normal physiological conditions and cancerous conditions...
  97. ncbi Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R
    Bhaumik B Patel
    John D Dingell VA Medical Center, Wayne State University, Detroit, MI 48201, USA
    Int J Cancer 122:267-73. 2008
    ..These changes were associated with decreased expression and activation (tyrosine phosphorylation) of EGFR, HER-2, HER-3 (72-100%) and IGF-1R (67%) as well as their downstream effectors such as Akt and cycloxygenase-2 (51-..
  98. pmc Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers
    Tatsuya Toyama
    Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho cho, Mizuho ku, Nagoya 467 8601, Japan
    BMC Cancer 8:309. 2008
    ..Triple-negative breast cancer (estrogen receptor-, progesterone receptor-, and HER2-negative) (TNBC) is a high risk breast cancer that lacks specific therapy targeting these proteins...
  99. pmc Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface
    Xuewu Zhang
    Department of Molecular and Cell Biology, and Howard Hughes Medical Institute, California Institute for Quantitative Sciences, University of California, Berkeley, California 94720, USA
    Nature 450:741-4. 2007
    Members of the epidermal growth factor receptor family (EGFR/ERBB1, ERBB2/HER2, ERBB3/HER3 and ERBB4/HER4) are key targets for inhibition in cancer therapy...
  100. ncbi Epidermal growth factor receptor exposed to oxidative stress undergoes Src- and caveolin-1-dependent perinuclear trafficking
    Elaine M Khan
    Signal Transduction Laboratory, Department of Internal Medicine, University of California, School of Medicine, Davis, California 95616, USA
    J Biol Chem 281:14486-93. 2006
    The epidermal growth factor (EGF) receptor (EGFR) has been found to be overexpressed in several types of cancer cells, and the regulation of its oncogenic potential has been widely studied...
  101. pmc Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain
    Jeffrey C Lee
    Department of Medical Oncology and Center for Cancer Genome Discovery, Dana Farber Cancer Institute Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS Med 3:e485. 2006
    ..Missense mutations in the EGFR kinase domain, for example, have recently been identified in patients who showed clinical responses to EGFR kinase ..

Research Grants66

  1. EGFR Mutations in non-Small Cell Lung Cancer
    Bruce Johnson; Fiscal Year: 2009
    ..Agents directed against the epidermal growth factor receptor have been developed (EGFR)...
  2. Molecular Mechanisms of EGF Signaling & Iressa/Tarceva Inhibition in NSCLC
    Karen S Anderson; Fiscal Year: 2010
    The epidermal growth factor receptor (EGFR) tyrosine kinase pathway has been demonstrated to be a key molecular target for cancer therapeutics including TKIs such as Iressa (gefinitib) and Tarceva (erlotinib)...
  3. Role of EGFR in DNA Repair and Radiation Response in Non Small Cell Lung Cancer
    CHAITANYA SURESH NIRODI; Fiscal Year: 2010
    ..among these NSCLCs is that they all harbor somatic, activating mutations in the tyrosine kinase domain (TKD) of the EGFR, that have also been linked to tumor sensitivity to small molecule tyrosine kinase inhibitors, gefitinib and ..
  4. Molecular Mechanisms of EGF Signaling & Iressa/Tarceva Inhibition in NSCLC
    Karen S Anderson; Fiscal Year: 2011
    DESCRIPTION (provided by applicant): The epidermal growth factor receptor (EGFR) tyrosine kinase pathway has been demonstrated to be a key molecular target for cancer therapeutics including TKIs such as Iressa (gefinitib) and Tarceva (..
  5. Coexpression of EGFRvlll/ErbB2 in Human Breast Cancer
    Careen Tang; Fiscal Year: 2005
    ..86 percent (43/50) of ErbB-2 positive primary breast tumors were co-expressed with EGFRvIII...
  6. The Odd-Even Effect of Polymorphic CA repeats in the 5' Regulatory Region of the
    IVAN GORLOV; Fiscal Year: 2007
    ..Epidermal growth factor receptor (EGFR) plays an important role in several processes directly involved in the incidence and progression of breast cancer...
  7. Illuminating Dynamic Receptor Clustering in the Epidermal Growth Factor Receptor
    BJOERN MARKUS REINHARD; Fiscal Year: 2010
    ..Factor Receptor Signal Transduction Pathway Using Plasmon Coupling Aberrant Epidermal Growth Factor Receptor (EGFR) activity has been linked to tumor formation and progression in malignant cells...
  8. Pyrophosphorolysis-activatable helicase dependent amplification assay for lung ca
    BERTRAND LEMIEUX; Fiscal Year: 2007
    ..Cancers over expressing the epidermal growth factor receptor (EGFR) have been shown to increase resistance to chemotherapy, thus increasing the risk of metastases...
  9. Epidermal Growth Factor Receptor Activation in Pulmonary Fibrosis
    WILLIAM DAVID HARDIE; Fiscal Year: 2010
    ..The epidermal growth factor receptor (EGFR) mediates signals induced by a family of growth factors including transforming growth factor-( (TGF-()...
  10. Targeting Akt/NF-kappa beta for Pancreatic Cancer Therapy
    Fazlul Sarkar; Fiscal Year: 2007
    ..Over-expression of epidermal growth factor receptor (EGFR) occurs in approximately 90% of human pancreatic cancer...
  11. Epidermal Growth Factor Receptor Activation in Pulmonary Fibrosis
    WILLIAM HARDIE; Fiscal Year: 2009
    ..The epidermal growth factor receptor (EGFR) mediates signals induced by a family of growth factors including transforming growth factor-( (TGF-()...
  12. Epidermal Growth Factor Receptor Activation in Pulmonary Fibrosis
    WILLIAM HARDIE; Fiscal Year: 2007
    ..The epidermal growth factor receptor (EGFR) mediates signals induced by a family of growth factors including transforming growth factor-( (TGF-()...
  13. Drug Resistance in Lung Cancer
    Pasi A Janne; Fiscal Year: 2010
    The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are effective therapeutic agents for patients with non-small cell lung cancer (NSCLC) whose tumors harbor somatic activating mutations ..
  14. Inhibition of P13k and MEK Pathways in the Treatment of Lung Cancer
    KWOK KIN contact WONG; Fiscal Year: 2010
    ..Recently, Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, have demonstrated clinical activity in ..
  15. Targeting the HGF/c-Met Pathway in Lung Cancer
    Jill M Siegfried; Fiscal Year: 2010
    ..We also demonstrated the ability of PGE2 to induce release of ligands for the epidermal growth factor receptor (EGFR) and to cause EGFR-dependent phosphorylation of c-Met, which was HGF-independent...
  16. MOLECULAR REGULATION OF CORNEAL WOUND HEALING
    Fu Shin X Yu; Fiscal Year: 2011
    ..The studies in the current grant period demonstrated that epidermal growth factor receptor (EGFR) is the key receptor tyrosine kinase activated upon wounding, and the wound-induced activation of EGFR and its ..
  17. MOLECULAR REGULATION OF CORNEAL WOUND HEALING
    Fu Shin X Yu; Fiscal Year: 2010
    ..The studies in the current grant period demonstrated that epidermal growth factor receptor (EGFR) is the key receptor tyrosine kinase activated upon wounding, and the wound-induced activation of EGFR and its ..
  18. Quantitative Analysis of Epidermal Growth Factor Receptor Signaling Networks
    Forest White; Fiscal Year: 2009
    ..be able to identify key nodes in the signaling network which regulate downstream biological response to activated ErbB receptor tyrosine kinases...
  19. Quantitative Analysis of Epidermal Growth Factor Receptor Signaling Networks
    Forest M White; Fiscal Year: 2010
    ..be able to identify key nodes in the signaling network which regulate downstream biological response to activated ErbB receptor tyrosine kinases...
  20. The Role of the EGF Receptor in Acute and Chronic Renal Injury
    Raymond Harris; Fiscal Year: 2010
    The Epidermal Growth Factor Receptor (EGFR;HER1) is widely expressed in the kidney, and previous studies have suggested roles for receptor activation in nephrogenesis, regulation of renal physiology and in aberrant growth in renal cell ..
  21. Epidermal growth factor receptor signaling in glioma
    Joon Uhm; Fiscal Year: 2006
    Mutations of the gene for epidermal growth factor receptor (EGFR) represent the most common oncogenic alteration in malignant gliomas. While the importance of aberrant EGFR activity in gliomas...
  22. PATTERN FORMATION IN THE DROSOPHILA EYE DISC
    Jessica E Treisman; Fiscal Year: 2010
    ..will investigate several such genes that are required for normal activity of the Epidermal growth factor receptor (EGFR) signaling pathway, which controls the proliferation, survival and differentiation of retinal progenitor cells and ..
  23. Bile acid-induced colon cancer cell proliferation
    Jean Pierre Raufman; Fiscal Year: 2009
    ..with M3 muscarinic receptors (M3R), thereby causing transactivation of epidermal growth factor receptors (EGFR)...
  24. Tyrosine Kinases in Renal Vasoconstrictor Signaling
    PAMELA CARMINES; Fiscal Year: 2007
    ..effects on vascular smooth muscle through AT1R-dependent transactivation of the epidermal growth factor receptor (EGFR)...